论文部分内容阅读
目的 探讨塞来昔布联合IMRT对老年中晚期非小细胞肺癌患者有效率及肿瘤标志物的影响效果?方法 选取来院治疗的非小细胞肺癌患者80例，并将患者随机划分成对照组和观察组，对对照组老年中晚期非小细胞肺癌患者施加单纯IMRT 放疗，对观察组患者实施塞来昔布联合IMRT的治疗?观察两组患者的有效率，分为CR?PR?SD?PD，计算ORR 的数据?另外观察两组患者治疗前后的CA125?CEA?SCCA 的标志物水平?结果 对比分析对照组和观察组老年中晚期非小细胞肺癌患者，明确观察组患者近期治疗有效率为28 例(70.“,”Objective To investigate the effect of celecoxib combined with IMRT on the effective rate and tumor markers in elderly patients with advanced non-small cell lung cancer. Methods A total of 80 patients with non-small cell lung cancer who came to the hospital for treatment were selected， and the patients were randomly divided into a control group and an observation group. The control group was given IMRT radiotherapy for the elderly patients with advanced non-small cell lung cancer， and the observation group was given celecoxib The treatment of cloth combined with IMRT. Observe the effective rate of the two groups of patients， divided into CR， PR， SD， PD， and calculate the ORR data. In addition， the levels of CA125， CEA and SCCA markers before and after treatment were observed in the two groups. Results A comparative analysis of the control group and the observation group of elderly patients with advanced non-small cell lung cancer showed that the effective rate of the observation group was 28 cases (70.00%)， which was signi?cantly higher than that of the control group， 15 cases (37.50%). There was a statistical difference (χ^2=8.498， P=0.004). Although the level of serum tumor markers in the control group of elderly patients with advanced non-small cell lung cancer after receiving routine clinical treatment will decrease， there is still a certain gap in the degree of change in the corresponding index compared with the observation group. In other words， before and after comprehensive treatment of elderly patients with advanced non-small cell lung cancer through celecoxib combined with IMRT， the reduction in serum tumor marker levels was signi?cantly higher than that of patients in the control group during the same period (P<0.05). Conclusion It is understood that in the clinical treatment of elderlypatients with advanced non-small cell lung cancer， it is necessary to strengthen the practical effect of celecoxib combined with IMRT based on the patient\'s physical condition and disease performance， and use standard and sophisticated radiotherapy equipment to treat the patient effective treatment can adjust the serum tumor marker levels in elderly patients with advanced non-small cell lung cancer and control the more and more serious cancerous organs in elderly patients with advanced non-small cell lung cancer. This makes the short-term curative effect and long-term effect of elderly patients with advanced non-small cell lung cancer. Survival rate rose to a certain height.